Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyRegional therapyDiseaseHepatocellular CarcinomaSubgroupICD10C22.0MeSHCarcinoma, HepatocellularLiver NeoplasmsSequenceChemotherapyChemo-substanceCisplatinDoxorubicinDrug-Eluting BeadsEpirubicinEthiodized oilIodixanolMitomycinNaCl 0.9%Polyvinyl alcoholChemo-substanceCisplatinDoxorubicinDrug-Eluting BeadsEpirubicinEthiodized oilIodixanolMitomycinNaCl 0.9%Polyvinyl alcoholChemo-substanceCisplatinDoxorubicinDrug-Eluting BeadsEpirubicinEthiodized oilIodixanolMitomycinNaCl 0.9%Polyvinyl alcoholChemo-substanceCisplatinDoxorubicinDrug-Eluting BeadsEpirubicinEthiodized oilIodixanolMitomycinNaCl 0.9%Polyvinyl alcoholNo. Substances235 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideNo. Substances37Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksEmetogenicityEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorCho SFohlen AFukushima TLammer JLencioni RYamada RDiseaseHepatozelluläres KarzinomHepatozelluläres Karzinom, größer 5cm, Zweitlinie nach DEB-TACE mit HepaspheresHepatozelluläres Karzinom, nicht resezierbar, ECOG 0-1Nicht resezierbares, nicht-metastasiertes hepatozelluläres KarzinomNicht resezierbares, nicht-metastasiertes hepatozelluläres Karzinom, Erstlinie, ECOG 0-1OriginAsan Medical Center, Department of Radiology, University of Ulsan College of Medicine, Seoul, KoreaCardiovascular and Interventional Radiology, Medical University Vienna, Austria, PRECISION V StudyDepartment of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, YokohamaDepartment of Interventional and Diagnostic Imaging, University Hospital of Caen, FranceDivision of Diagnostic Imaging and Intervention, Pisa University Hospital, University of PisaDivision of Vascular and Interventional Radiology, Department of Radiology, Medical University of South Carolina, Charleston, SC, USAProtocols in Revision 6 protocols foundProtocols under revision.cTACE - Cisplatin 2 / Ethiodized oil 12.8, Hepatocellular Carcinoma (PID2879 V1.0)cTACE - Doxorubicin 100 / Ethiodized oil 12.8, Hepatocellular Carcinoma (PID2932 V1.0)cTACE - Mitomycin 10 / Ethiodized oil 6.4, Hepatocellular Carcinoma (PID2866 V1.0)DEB-TACE - Doxorubicin 100, Hepatocellular Carcinoma (PID2880 V1.0)DEB-TACE - Doxorubicin 75, Hepatocellular Carcinoma (PID2931 V1.0)DEB-TACE - Epirubicin 50, Hepatocellular Carcinoma (PID2878 V1.0)
